Wanbury Limited (WANBURY.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹176.02 (+5.77%) as of
Key statistics
- Market cap
- 6.15B
- P/E (TTM)
- 10.81
- EPS (TTM)
- 16.28
- Dividend yield
- 0.00%
- 52-week range
- 161.50 – 358.85
- Beta
- 0.18
- Revenue (TTM)
- 6.53B
- Profit margin
- 8.56%
- Volume
- 111.08k
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid, Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was founded in 1988 and is headquartered in Navi Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Navi Mumbai, India
- Employees
- 1,200
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.